13 completed, 6 unknown, 4 recruiting, 3 terminated. 31 Phase 2, 6 Phase 1, 3 Phase 3.
Follow Supranuclear Palsy, Progressive: new trials by email Literature Review of Supranuclear Palsy, Progressive trials Research Report on Supranuclear Palsy, Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies NIO752, Placebo - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 48 | 2026-10-23 | 2026-10-09 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-10-01 | 2026-11-05 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1 AADvac1, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 146 | 2026-07-29 | 2026-11-05 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31 LM11A-31, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 147 | 2026-07-29 | 2026-11-05 |
| The Progressive Supranuclear Palsy Clinical Trial Platform AADvac1, LM11A-31 - Progressive Supranuclear Palsy(PSP) | Phase 2 | Recruiting | Adam Boxer | 440 | 2026-07-29 | 2026-11-10 |
| Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauopathies ARO-MAPT-SC, Placebo - Alzheimer Disease, Tauopathies | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 160 | 2025-11-18 | 2026-11-10 |
| A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) FNP-223, Placebo - Progressive Supranuclear Palsy | Phase 2 | Active not recruiting | Ferrer Internacional S.A. | 241 | 2024-07-23 | 2025-10-15 |
| The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism Nicotinamide Riboside, Placebo - Progressive Supranuclear Palsy, Multiple System Atrophy | Phase 2 | Recruiting | Haukeland University Hospital | 330 | 2024-03-05 | 2025-01-10 |
| AMX0035 and Progressive Supranuclear Palsy AMX0035, Placebo - Progressive Supranuclear Palsy, PSP | Phase 2 / Phase 3 | Completed | Amylyx Pharmaceuticals Inc. | 139 | 2023-12-21 | 2026-04-30 |
| Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 GV1001 Placebo, GV1001 1.12mg - Progressive Supranuclear Palsy | Phase 2 | Completed | GemVax & Kael | 67 | 2023-12-12 | 2025-11-21 |
| GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg - Progressive Supranuclear Palsy | Phase 2 | Completed | GemVax & Kael | 78 | 2023-06-14 | 2026-02-10 |
| A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) TPN-101, 100 mg/day, TPN-101, 200 mg/day, TPN-101, 400 mg/day - Progressive Supranuclear Palsy | Phase 2 | Completed | Transposon Therapeutics, Inc. | 42 | 2021-12-12 | 2026-04-08 |
| Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Droxidopa, Placebo Oral Tablet - Parkinson Disease, Multiple System Atrophy | Phase 2 | Withdrawn | Loma Linda University | 2021-12-01 | 2022-03-02 | |
| RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY RT001, Placebo - Progressive Supranuclear Palsy | Phase 2 | Unknown | Biojiva LLC | 40 | 2021-06-23 | 2021-06-25 |
| Rho Kinase (ROCK) Inhibitor in Tauopathies - 1 Fasudil - Progressive Supranuclear Palsy, Corticobasal Syndrome | Phase 2 | Unknown | Woolsey Pharmaceuticals | 15 | 2021-01-22 | 2022-06-03 |
| Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks Tolfenamic Acid, Placebos - Progressive Supranuclear Palsy | Phase 1 / Phase 2 | Unknown | NeuroTau, Inc. | 24 | 2021-01-01 | 2020-02-05 |
| A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP AZP2006 oral solution, Placebo oral solution - Progressive Supranuclear Palsy | Phase 2 | Completed | AlzProtect SAS | 36 | 2020-06-22 | 2025-03-17 |
| Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) NBMI, Placebo - Progressive Supranuclear Palsy, Multiple System Atrophy | Phase 2 | Completed | EmeraMed | 20 | 2019-09-16 | 2021-09-23 |
| An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) ABBV-8E12, Placebo solution for IV infusion on Day 15 - Progressive Supranuclear Palsy (PSP) | Phase 2 | Terminated | AbbVie | 142 | 2018-01-24 | 2021-02-03 |
| Study of BIIB092 in Participants With Progressive Supranuclear Palsy BIIB092, Placebo - Supranuclear Palsy, Progressive | Phase 2 | Terminated | Biogen | 490 | 2017-06-01 | 2020-12-21 |
Showing 20 of 31. Sign in to see all of them.
Corticobasal Degeneration (4) · Multiple System Atrophy (4) · Tauopathies (4) · Frontotemporal Dementia (3) · Neurodegenerative Diseases (2) · Parkinson Disease (2) · Pick Disease of the Brain (2) · Alzheimer Disease (1) · Dementia (1) · Disease Progression (1) · Fatigue (1) · Frontotemporal Lobar Degeneration (1) · Nerve Degeneration (1) · Nervous System Diseases (1)
Basal Ganglia Diseases (31) · Brain Diseases (31) · Central Nervous System Diseases (31) · Cranial Nerve Diseases (31) · Eye Diseases (31) · Movement Disorders (31) · Neurologic Manifestations (31) · Ocular Motility Disorders (31) · Ophthalmoplegia (31) · Paralysis (31) · Pathological Conditions, Signs and Symptoms (31) · Signs and Symptoms (31) · Nervous System Diseases (30) · Neurodegenerative Diseases (29) · Tauopathies (27)
AADvac1 (2) · LM11A-31 (2) · Saline Solution (2) · coenzyme Q10 (2) · tilavonemab (2) · Acetylcarnitine (1) · Donepezil (1) · Droxidopa (1) · Glial Cell Line-Derived Neurotrophic Factor (1) · Lithium (1) · RT001 (1) · Rivastigmine (1) · Safflower Oil (1) · Thioctic Acid (1) · Valproic Acid (1)
Adam Boxer (3) · AbbVie (2) · GemVax & Kael (2) · Allon Therapeutics (1) · AlzProtect SAS (1) · Amylyx Pharmaceuticals Inc. (1) · Arrowhead Pharmaceuticals (1) · Biogen (1) · Biojiva LLC (1) · EmeraMed (1) · Ferrer Internacional S.A. (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · German Parkinson Study Group (GPS) (1) · Groupe Hospitalier Pitie-Salpetriere (1) · Haukeland University Hospital (1)
United States (18) · France (8) · Germany (8) · Italy (6) · Canada (5) · Australia (4) · Spain (4) · United Kingdom (4) · Japan (3) · South Korea (3) · Austria (1) · Greece (1) · Hungary (1) · New Zealand (1) · Norway (1)
Adam Boxer, MD, PhD (3) · Anne-Marie Wills, MD (3) · Irene Litvan, MD (3) · Julio Rojas-Martinez, MD, PhD (3) · Sang Jae Kim (2) · Adam Boxer, M.D., PhD. (1) · Bertrand Gaymard, MD, PhD (1) · Charalampos Tzoulis, MD, PhD (1) · Claire Henchcliffe, MD DPhil (1) · Daniela Berg, Doctor (1) · Diana Apetauerova, MD (1) · Khashayar Dashtipour, M.D. Ph.D. (1) · Marwan Sabbagh, MD (1)
PMID 38825840, PMID 24438512, PMID 24873720, PMID 27136096, PMID 27160012, PMID 28436538, PMID 33609476, PMID 34385707, PMID 34712113, PMID 34736158, PMID 40368603, PMID 41239890
R01AG085029 (3), 2016 (2), 2017 (1), 2023 (1)